Economic burden of comorbidities in patients with psoriasis is substantial

Kimball, Alexa B.; Guérin, Annie; Tsaneva, Magda; Yu, Aixi; Wu, EQ; Gupta, SR; Bao, Yanjun; Mulani, P.M.

doi:10.1111/j.1468-3083.2010.03730.x

Cited by 118 publications

(102 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9 Additionally, the comorbid conditions in patients with psoriasis represent a substantial economic burden to society. 10 According to American Academy of Dermatology psoriasis treatment guidelines, several treatment options are available for psoriasis patients depending on the severity of the disease.…”

Section: ■■ Methods Study Designmentioning

confidence: 99%

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Feldman¹,

Zhao²,

Navaratnam³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

Section: ■■ Methods Study Designmentioning

confidence: 99%

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Feldman¹,

Zhao²,

Navaratnam³

et al. 2015

JMCP

View full text Add to dashboard Cite

show abstract

“…347 Therefore, we performed a literature search for COI studies 348 for the period from January 2010 to December 2013 using 349 the same search terms and databases as Raho et al [9].Our 350 search identified a further nine publications [28][29][30][31][32][33][34][35][36], seven 351 of which involved psoriasis patients with biological treat-352 ment. In the COI analyses conducted by Fonia et al (UK) 353 [28] and Driessen et al (the Netherlands) [29] all patients 354 were treated with biological drugs.…”

mentioning

confidence: 99%

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

et al. 2014

View full text Add to dashboard Cite

10 Background Despite the widespread availability of bio-11 logical drugs in psoriasis, there is a shortage of disease 12 burden studies. 13 Objectives To assess the cost-of-illness and quality of 14 life of patients with moderate to severe psoriasis in 15 Hungary. 16 Methods Consecutive patients with Psoriasis Area and 17 Severity Index (PASI) [ 10 and Dermatology Life Quality 18 Index (DLQI) [ 10, or treated with traditional systemic 19 (TST) or biological systemic treatment (BST) were inclu-20 ded. Demographic data, clinical characteristics, psoriasis 21 related medication, health care utilizations and employ-22 ment status in the previous 12 months were recorded. 23 Costing was performed from the societal perspective 24 applying the human capital approach. Quality of life was 25 assessed using DLQI and EQ-5D measures. 26 Results Two-hundred patients were involved (females 27 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) 28 patients were on BST. Mean PASI, DLQI and EQ-5D 29 scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), 30 respectively. The mean total cost was €9,254/patient/year 31 (SD 8,502) with direct costs accounting for 86 %. The 32 main cost driver was BST (mean €7,339/patient/year).

show abstract

“…Amerika Birleşik Devletleri'nde 114,512 hastanın değerlendirildiği bir çalışmada hastaların %51'inde bir veya daha fazla komorbidite saptanmıştır. Tüm eşlik eden komorbiditeler içersinde %27 ile hiperlipidemi ve %25 ile hipertansiyon en sık karşılaşılanlar olarak rapor edilmiştir 12,13 . Onsun ve ark.…”

Section: Discussionunclassified

The effect of psoriasis treatment on body composition, components of metabolic syndrome and psoriatic arthritis

Tamer¹,

Gürer²

2015

TURKDERM

View full text Add to dashboard Cite

Background and Design:Psoriasis is a chronic inflammatory immune-mediated skin disorder with unknown etiology. Chronic inflammation in psoriasis has a role in the development of metabolic and vascular disorders related with associating comorbidities. Recent studies have suggested a strong association between psoriasis and obesity, which is one of the components of metabolic syndrome, and emphasized the complex relationship of psoriasis treatment with psoriasis and body mass index (BMI). In this study, our aim was to investigate the effect of psoriasis treatment with methotrexate, cyclosporine and biological agents on body composition, comorbidities and associated laboratory findings. Materials and Methods: Seventy-nine patients treated with methotrexate, cyclosporin and biological agents were included in our study. Demographic characteristics, body composition analysis, psoriasis-related comorbidities and laboratory examinations were evaluated before and after 12 weeks of systemic treatment. Results: Comorbidities and metabolic syndrome tended to be more frequent in the anti-tumor necrosis factor alpha (anti-TNF-α)-treated group. Increase in body fat and weight detected in patients receiving biologic drug therapy. Conclusion:The results of our study showed that patients with severe psoriasis with longer disease duration were more likely to have metabolic syndrome because of severe and long-term inflammation in the pathogenesis of comorbidities. (Turkderm 2015; 49: 41-4)

show abstract

Economic burden of comorbidities in patients with psoriasis is substantial

Abstract: Comorbidities present a significant economic burden in patients with psoriasis.

Cited by 118 publications

References 30 publications

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Patterns of Medication Utilization and Costs Associated with the Use of Etanercept, Adalimumab, and Ustekinumab in the Management of Moderate-to-Severe Psoriasis

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

The effect of psoriasis treatment on body composition, components of metabolic syndrome and psoriatic arthritis

Contact Info

Product

Resources

About